SynthesisBMC gastroenterology2013
Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis.
Synthesis in BMC gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03322280 (TACE Combined With Iodine-125 Seeds Implantation Versus TACE Alone for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus), which is not on this map. Cited by 107 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TACE Combined With Iodine-125 Seeds Implantation Versus TACE Alone for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective, Multicenter, Randomized, Controlled Study
Who cites it
107 citing papers in PubMed, 7 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.Clinical and molecular hepatology · 2022Guideline
- 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.Korean journal of radiology · 2019Guideline
- 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.Gut and liver · 2019Guideline
- Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition.Oncotarget · 2017Guideline
- Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.Oncotarget · 2016Pooled it
- Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2015Guideline
- Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis.PloS one · 2014Pooled it
- Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study.Hepatology international · 2022Trial
- Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma.Cancer reports (Hoboken, N.J.) · 2021Trial
- Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.Medical oncology (Northwood, London, England) · 2015Trial
- Quantitative Hepatobiliary Phase Signal Analysis of HCC Nodules on Gd-EOB-DTPA-Enhanced MRI: A Potential Imaging Biomarker Associated with Disease Control After Conventional Transarterial Chemoembolization (cTACE).Journal of clinical medicine · 2026Article
- A machine learning approach to identify optimal candidates for transarterial chemoembolization in unresectable HBV-related hepatocellular carcinoma complicated by first-branch portal vein tumor thrombus: a multicenter study.Frontiers in oncology · 2026Article
- Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study.Journal of hepatocellular carcinoma · 2025Article
- Management strategies for advanced hepatocellular carcinoma with portal vein tumor thrombosis.Ewha medical journal · 2025Review
- Clinical significance of surgical resection for hepatocellular carcinoma with portal vein invasion: a nationwide cohort study.Hepatobiliary surgery and nutrition · 2024Article
- Transarterial Therapy for Hepatocellular Carcinoma Invading the Bile Duct.Interventional radiology (Higashimatsuyama-shi (Japan) · 2024Review
- A Machine Learning Model Based on Counterfactual Theory for Treatment Decision of Hepatocellular Carcinoma Patients.Journal of hepatocellular carcinoma · 2024Article
- Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV.Frontiers in immunology · 2024Article
- The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough transarterial chemoembolization (TACE) has been used extensively for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), no consensus has been reached and an evidence base for practice is lacking. This meta-analysis evaluated the efficacy and safety of TACE for treatment of HCC with PVTT.
methodsOvid Medline, EMBASE, Web of Knowledge, and Cochrane library databases were searched up to August 2012 for controlled trials assessing TACE in patients with PVTT. Data concerning the study design, characteristics of trials, and outcomes were extracted. Hazard ratio (HR) and 95% confidence interval (CI) were calculated using random effects models.
resultsEight controlled trials involving 1601 HCC patients were included. TACE significantly improved the 6-month (HR, 0.41; 95% CI: 0.32-0.53; z, 6.28; p = 0.000) and 1-year (HR, 0.44; 95% CI: 0.34-0.57; z, 6.22; p = 0.000) overall survival of patients with PVTT compared with conservative treatment. Subgroup analyses showed that TACE was significantly effective in HCC patients whether with main portal vein (MPV) obstruction or with segmental PVTT. Fatal complications were rare, even in patients with MPV obstruction. Temporary liver decompensation and postembolization syndrome occurred frequently. However, they could be treated successfully with conservative treatment.
conclusionsTACE, as a safe treatment, has potential for incurring a survival benefit for advanced HCC with PVTT, even with MPV obstruction. Further large randomized controlled trials may be needed to confirm this result.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.